CD163 expression is present in cutaneous histiocytomas but not in atypical fibroxanthomas

American Journal of Clinical Pathology

Volumn 133, Issue 6, 2010, Pages 915-921

  Sachdev, Reena ^a,c   Robbins, Jason ^a,d   Kohler, Sabine ^a,b   Vanchinathan, Vijay ^a   Schwartz, Erich J ^a   Sundram, Uma N ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NONE

Author keywords

Atypical fibroxanthomas; CD163; Cutaneous; Histiocytic

Indexed keywords

CD163 ANTIGEN; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; SCAVENGER RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL FIBROXANTHOMA; CHILD; EPITHELIOID CELL HISTIOCYTOMA; FIBROXANTHOMA; HISTIOCYTOMA; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; INFANT; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOHISTIOCYTOSIS; SCHOOL CHILD; TUMOR DIFFERENTIATION; XANTHOGRANULOMA; XANTHOMA; CHEMISTRY; DERMATOFIBROMA; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; INFANT; MIDDLE AGED; NEPRILYSIN; RECEPTORS, CELL SURFACE; RECEPTORS, SCAVENGER; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953008492     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP88IRBPXQZYIR     Document Type: Article

References (18)

1. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
2. Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29:617-624.
3. Weaver LK, Pioli PA, Wardwell K, et al. Up regulation of human monocyte CD163 upon activation of cell surface toll like receptors. J Leuk Biol. 2007;81:1-9.
4. Sachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and factor XIIIa. J Cutan Pathol. 2006;33:353-360.
5. Miettinen M, Fetsch JF. Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases. Am J Surg Pathol. 2006;30:521-528.
6. Burg G, Jaffe ES, Kempf W, et al. Haematolymphoid tumors. In: LeBoit PE, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:217-225. WHO Classification of Tumours.
7. McKee PH. What is atypical fibroxanthoma? carcinoma, sarcoma, both, or neither? Presented at the Companion Meeting (American Society of Dermatopathology) of the 95th Annual Meeting of the United States and Canadian Academy of Pathology; February 12, 2006; Atlanta, GA.
8. de Feraudy S, Mar N, McCalmont T. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol. 2008;32:1111-1122.
9. Pouryazdanparast P, Yu L, Cutlan JE, et al. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859-864.
10. Hartel PH, Jackson J, Ducatman BS, et al. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol. 2006;33(suppl 2):24-28. (Pubitemid 44370073)
11. Hultgren TL, DiMaio DJ. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol. 2007;34:415-419.
12. Bindl JM, Warnke RA. Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol. 1986;85:490-493.
13. Sundram U, Harvell J, Rouse R, et al. Expression of the B cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and melan A. Mod Pathol. 2003;16:802-810. (Pubitemid 37011076)
14. Busam KJ, Rosai J, Iversen K, et al. Xanthogranulomas with inconspicuous foam cells and giant cells mimicking malignant melanoma: a clinical, histologic, and immunohistochemical study of three cases. Am J Surg Pathol. 2000;24:864-869. (Pubitemid 30366275)
15. Busam KJ, Granter SR, Iversen K, et al. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. Am J Dermatopathol. 2000;22:237-241. (Pubitemid 30368343)
16. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1-29.
17. Glusac GJ, Barr RJ, Everett MA, et al. Epithelioid cell histiocytoma: a report of 10 cases including a new cellular variant. Am J Surg Pathol. 1994;18:583-590.
18. Monteagudo C, Calduch L, Navarro S, et al. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol. 2002;117:126-131 (Pubitemid 34052482)